Takeda Pharmaceutical Company Limited
Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2026 (IFRS, Consolidated)
Filed with TSE ·
Watch Takeda Pharmaceutical's latest callTakeda Pharmaceutical (Tokyo:4502) Q1 2026 Earnings Call · Replay · Jul 30Read the transcript of Takeda Pharmaceutical (Tokyo:4502) Q1 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Takeda Pharmaceutical Co. Ltd. on 6ix
In the deck
Earlier from Takeda Pharmaceutical
- Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
- Takeda Pharmaceutical to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29
- Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
- Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
- U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Later from Takeda Pharmaceutical
All Takeda Pharmaceutical news releasesFollow Takeda Pharmaceutical into a list and get an email when it puts out news.
Follow Takeda Pharmaceutical